Oncolytics Biotechnology Incorporated
Company Income Statement
| Dec 2007 | Dec 2006 | Dec 2005 | Dec 2004 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 11.39M | 9.04M | 8.00M | 5.92M |
| Research & Development | 4.56M | 3.46M | 2.71M | 4.56M |
| Operating Income before D & A (EBITDA) | -15.95M | -12.51M | -10.71M | -10.48M |
| Depreciation & Amortization | 1.01M | 795.46K | 736.07K | 626.51K |
| Interest Income | 1.22M | 1.06M | 673.69K | 583.18K |
| Other Income - Net | -8.92K | -30.28K | -217.42K | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -269.92K |
| Total Income Before Interest Expenses (EBIT) | -15.75M | -12.27M | -10.99M | -10.80M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -15.75M | -12.27M | -10.99M | -10.80M |
| Income Taxes | 0.00 | 0.00 | -1.31K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -15.75M | -12.27M | -10.99M | -10.80M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -15.75M | -12.27M | -10.99M | -10.80M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -15.75M | -12.27M | -10.99M | -10.80M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-15.75M | -12.27M | -10.99M | -10.53M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -15.75M | -12.27M | -10.99M | -10.80M |
| Basic EPS from Continuing Ops. | -0.39 | -0.33 | -0.34 | -0.38 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.39 | -0.33 | -0.34 | -0.38 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.39 | -0.33 | -0.34 | -0.38 |
| Basic Normalized Net Income/Share | -0.39 | -0.33 | -0.34 | -0.37 |
| EPS fr Continuing Ops. | -0.39 | -0.33 | -0.34 | -0.38 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.39 | -0.33 | -0.34 | -0.38 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.39 | -0.33 | -0.34 | -0.38 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.39 | -0.33 | -0.34 | -0.37 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Quotes
News & Commentary
Financials
Company Information
Ratings
Find more premium investing ideas